Abstract:l-3,4-dihydroxyphenylalanine (l-DOPA) is an effective treatment for Parkinson's disease (PD); however, long-term treatment induces l-DOPA-induced dyskinesia (LID). To elucidate its pathophysiology, we developed a mouse model of LID by daily administration of l-DOPA to PD male ICR mice treated with 6-hydroxydopamine (6-OHDA), and recorded the spontaneous and cortically evoked neuronal activity in the external segment of the globus pallidus (GPe) and substantia nigra pars reticulata (SNr), the connecting and output nuclei of the basal ganglia, respectively, in awake conditions. Spontaneous firing rates of GPe neurons were decreased in the dyskinesia-off state (≥24 h after l-DOPA injection) and increased in the dyskinesia-on state (20–100 min after l-DOPA injection while showing dyskinesia), while those of SNr neurons showed no significant changes. GPe and SNr neurons showed bursting activity and low-frequency oscillation in the PD, dyskinesia-off, and dyskinesia-on states. In the GPe, cortically evoked late excitation was increased in the PD and dyskinesia-off states but decreased in the dyskinesia-on state. In the SNr, cortically evoked inhibition was largely suppressed, and monophasic excitation became dominant in the PD state. Chronic l-DOPA treatment partially recovered inhibition and suppressed late excitation in the dyskinesia-off state. In the dyskinesia-on state, inhibition was further enhanced, and late excitation was largely suppressed. Cortically evoked inhibition and late excitation in the SNr are mediated by the cortico-striato-SNr direct and cortico-striato-GPe-subthalamo-SNr indirect pathways, respectively. Thus, in the dyskinesia-on state, signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed, underlying LID. SIGNIFICANCE STATEMENT Parkinson's disease (PD) is caused by progressive loss of midbrain dopaminergic neurons, characterized by tremor, rigidity, and akinesia, and estimated to affect around six million people world-wide. Dopamine replacement therapy is the gold standard for PD treatment; however, control of symptoms using l-3,4-dihydroxyphenylalanine (l-DOPA) becomes difficult over time because of abnormal involuntary movements (AIMs) known as l-DOPA-induced dyskinesia (LID), one of the major issues for advanced PD. Our electrophysiological data suggest that dynamic changes in the basal ganglia circuitry underlie LID; signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed. These results will provide the rationale for the development of more effective treatments for LID.

Identification of Metabolite Biomarkers for L-DOPA-induced Dyskinesia in a Rat Model of Parkinson's Disease by Metabolomic Technology.

Genome‐wide Microarray Analysis Identifies a Potential Role for Striatal Retrograde Endocannabinoid Signaling in the Pathogenesis of Experimental L‐dopa‐induced Dyskinesia

Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation

Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia Through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease

The Dynamics of Dopamine D 2 Receptor-Expressing Striatal Neurons and the Downstream Circuit Underlying L-Dopa-Induced Dyskinesia in Rats

Distinct Anti-Dyskinetic Effects of Amantadine and Group II Metabotropic Glutamate Receptor Agonist LY354740 in a Rodent Model: an Electrophysiological Perspective

Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia

Effects of L-dopa on Cells Expressing D2 Receptors and Level of Dopamine Transmitter in Hemiparkinsonian Rats

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Activation of mGlu 2/3 receptors in the striatum alleviates L-DOPA-induced dyskinesia and inhibits abnormal postsynaptic molecular expression

Differential activation states of direct pathway striatal output neurons during L-DOPA-induced dyskinesia development.

Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry

Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease

L-DOPA-induced Dyskinesia in a Rat Model of Parkinson's Disease is Associated with the Fluctuational Release of Norepinephrine in the Sensorimotor Striatum.

Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of L-DOPA-Induced Dyskinesia

The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and -mediated Parkinson’s disease – a large-scale targeted metabolomics study

Inhibition of Glycogen Synthase Kinase-3β (Gsk-3Β) As Potent Therapeutic Strategy to Ameliorates L-dopa-induced Dyskinesia in 6-OHDA Parkinsonian Rats

Antidyskinetic Effects of MEK Inhibitor Are Associated with Multiple Neurochemical Alterations in the Striatum of Hemiparkinsonian Rats

Mechanism of Over-Activation in Direct Pathway Mediated by Dopamine D₁ Receptor in Rats with Levodopa-Induced Dyskinesia.

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)

Inhibition of Striatal Dopamine D5 Receptor Attenuates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.